Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-7535 Drug Interactions in Obese or Overweight Subjects
NCT07269756Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-7535 in obesity, sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum concentration at 63 days, Area under the concentration-time curve from time zero to the time of the last quantifiable concentration at 63 days and 1 more. Started Dec 2025; status: completed.
02
Drugs
HRS-7535
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07269756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07269756.